Abstract:Background and aim: Human papillomavirus (HPV) is an oncogenic agent that causes over 90% of cases of cervical cancer in the world. Currently available prophylactic vaccines are type specific and have less therapeutic efficiency. Therefore, we aimed to predict the potential species-specific and therapeutic epitopes from the protein sequences of HPV45 by using different immunoinformatics tools. Methods: Initially, we determined the antigenic potential of late (L1 and L2) and early (E1, E2, E4, E5, E6, and E7) proteins. Then, major histocompatibility complex class I-restricted CD8(+) T-cell epitopes were selected based on their immunogenicity. In addition, epitope conservancy, population coverage (PC), and target receptor-binding affinity of the immunogenic epitopes were determined. Moreover, we predicted the possible CD8(+), nested interferon gamma (IFN-gamma)-producing CD4(+), and linear B-cell epitopes. Further, antigenicity, allergenicity, immunogenicity, and system biology-based virtual pathway associated with cervical cancer were predicted to confirm the therapeutic efficiency of overlapped epitopes. Results: Twenty-seven immunogenic epitopes were found to exhibit cross-protection (>= 55%) against the 15 high-risk HPV strains (16, 18, 31, 33, 35, 39, 51, 52, 56, 58, 59, 68, 69, 73, and 82). The highest PC was observed in Europe (96.30%), North America (93.98%), West Indies (90.34%), North Africa (90.14%), and East Asia (89.47%). Binding affinities of 79 docked complexes observed as global energy ranged from -10.80 to -86.71 kcal/mol. In addition, CD8(+) epitope-overlapped segments in CD4(+) and B-cell epitopes demonstrated that immunogenicity and IFN-gamma-producing efficiency ranged from 0.0483 to 0.5941 and 0.046 to 18, respectively. Further, time core simulation revealed the overlapped epitopes involved in pRb, p53, COX-2, NF-X1, and HPV45 infection signaling pathways. Conclusion: Even though the results of this study need to be confirmed by further experimental peptide sensitization studies, the findings on immunogenic and IFN-gamma-producing CD8(+) and overlapped epitopes provide new insights into HPV vaccine development.

Computational Modeling of Immune Response Triggering Immunogenic Peptide Vaccine Against the Human Papillomaviruses to Induce Immunity Against Cervical Cancer.

Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine Against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches

Designing and immunomolecular analysis of a new broad-spectrum multiepitope vaccine against divergent human papillomavirus types

Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer

Beyond prevention: in silico designing a one-two punch novel therapeutic vaccine candidate against major oncoproteins of HPV 16, 18, 31, and 45 and subsequent cervical cancer

Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins

A Comparative Analysis of Computational Strategies in Multi-Epitope Vaccine Design Against Human Papillomavirus and Cervical Cancer

Immunomics Datasets and Tools: to Identify Potential Epitope Segments for Designing Chimeric Vaccine Candidate to Cervix Papilloma.

Cancer Immunoinformatics: A Promising Era in the Development of Peptide Vaccines for Human Papillomavirus-induced Cervical Cancer

Computational Identification, Characterization and Validation of Potential Antigenic Peptide Vaccines from Hrhpvs E6 Proteins Using Immunoinformatics and Computational Systems Biology Approaches.

Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods

In silico design of a multi-epitope vaccine against HPV16/18

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Designing of CD8 + and CD8 + -overlapped CD4 + epitope vaccine by targeting late and early proteins of human papillomavirus.

Design and evaluation of a multi-epitope DNA vaccine against HPV16

A novel therapeutic multiepitope vaccine based on oncoprotein E6 and E7 of HPV 16 and 18: An in silico approach

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

Characterization of an Escherichia Coli-Derived Triple-Type Chimeric Vaccine Against Human Papillomavirus Types 39, 68 and 70

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine

Epitope Clustering Analysis for Vaccine-Induced Human Antibodies in Relationship to a Panel of Murine Monoclonal Antibodies Against HPV16 Viral Capsid.